Canada's Drug Agency Recommends Conditional Reimbursement for Yorvipath in Chronic Hypoparathyroidism
核心洞察
Canada's Drug Agency (CDA-AMC) has recommended conditional public reimbursement for Yorvipath (palopegteriparatide injection) in adults with chronic hypoparathyroidism (搜索) inadequately controlled with conventional therapy.
Yorvipath is a parathyroid hormone (PTH) replacement therapy authorized by Health Canada on January 28, 2026, and supported by evidence from the Phase 3 PaTHway trial.
The recommendation marks an important milestone, though final listing decisions rest with participating federal, provincial, and territorial drug plans and hinge on price negotiation.
Pendopharm (搜索), a division of Pharmascience Inc., in collaboration with Ascendis Pharma A/S, announced that Canada's Drug Agency (CDA-AMC) has recommended that Yorvipath (palopegteriparatide injection) be reimbursed with conditions by participating public drug plans for eligible adults with chronic hypoparathyroidism (搜索) that are not adequately controlled with conventional therapy.
Yorvipath is a parathyroid hormone (PTH) replacement therapy for the treatment of chronic hypoparathyroidism (搜索) in adults, authorized by Health Canada on January 28, 2026. The CDA-AMC recommendation represents an important step in the Canadian public reimbursement process. The CDA-AMC review considered evidence from the Phase 3 PaTHway clinical trial, which evaluated palopegteriparatide in adults with chronic hypoparathyroidism.
A Milestone for Patients with Uncontrolled Disease
"This recommendation is an important milestone for adults whose chronic hypoparathyroidism (搜索) remains inadequately controlled despite conventional therapy," said Jad Isber, Vice-President and General Manager, Pendopharm (搜索). "We welcome CDA-AMC's recognition of the needs of eligible adults with chronic hypoparathyroidism and will continue to work through the Canadian reimbursement process."
Dr. Aliya Khan, Clinical Professor of Medicine and Director of the Calcium Disorders Clinic at McMaster University, Hamilton, Ontario, described the clinical context underlying the recommendation. "People living with chronic hypoparathyroidism (搜索) can face significant daily challenges even while taking intensive calcium and active vitamin D therapy," Dr. Khan said. "Conventional therapy generally consists of oral calcium and active vitamin D. Guidelines suggest conventional therapy as first-line; PTH therapy may be considered when conventional therapy is unsatisfactory. For appropriate adults, a PTH replacement therapy may offer a different treatment approach by addressing the underlying hormone deficiency."
Clinical Evidence and Durability
The recommendation follows a clinical record built largely on the Phase 3 PaTHway trial, which tracked sustained response in adults with hypoparathyroidism across three years. That durability argument carries weight in a condition where patients typically cycle through high-dose calcium and calcitriol indefinitely, often with incomplete symptom control and persistent hypocalcemia risk. Ascendis Pharma had already secured FDA approval in August 2024, so the Canadian agency had a substantial post-approval evidence base to evaluate, not just trial data.
Reimbursement Conditions and Next Steps
The conditions attached to the recommendation matter: coverage is not automatic, and negotiated price will almost certainly determine how quickly provincial formularies act. The practical bottleneck now is price negotiation with the pan-Canadian Pharmaceutical Alliance. CDEC conditional recommendations routinely stall at that stage, and chronic hypoparathyroidism (搜索) affects a small patient population, which cuts both ways: the per-patient budget impact is manageable, but the absence of a large comparator pool makes cost-effectiveness modeling contentious.
Natpara (recombinant human PTH 1-84) is the established hormonal alternative against which payers will benchmark value, and its formulary history across Canadian provinces will shape how aggressively they negotiate. Participating federal, provincial, and territorial drug plans will make their own final listing decisions.
Defining "Inadequate Control"
The clinical team to watch is the one managing patients who meet the "inadequate control" threshold the recommendation defines. That eligibility criterion will be the operational gate: if the bar is drawn narrowly around documented hypocalcemia episodes or hospitalization, uptake stays limited regardless of reimbursement status. How the final coverage criteria define "inadequately controlled" is the single specification worth tracking as provincial decisions follow.
Patty Keating, Executive Director of the HypoPARAthyroidism Association (USA), underscored the significance for the patient community. "This recommendation is meaningful for our community because it recognizes the challenges experienced by some people living with chronic hypoparathyroidism (搜索) and the need for access discussions for eligible patients," Keating said.